This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
